Who is sponsoring NCT00930059?

NCT00930059 is sponsored by Pfizer.

What condition does NCT00930059 study?

NCT00930059 studies Alzheimer's Disease.

What drugs are being tested in NCT00930059?

Interventions: PF-04447943, Placebo.

What is the status of NCT00930059?

NCT00930059 is currently COMPLETED.

Last reviewed 2020-11-19 · How we verify

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.

Details

Lead sponsor	Pfizer
Phase	PHASE2
Status	COMPLETED
Enrolment	191
Start date	Thu Sep 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 22 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Alzheimer's Disease

Interventions

PF-04447943
Placebo

Countries

Chile, Canada, United States, Czechia